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Abstract
Background: New malaria treatment guidelines in Tanzania have led to the large-scale deployment of artemether-
lumefantrine (Coartem®), popularly known as ALu or dawa mseto. Very little is known about how people in malaria
endemic areas interpret policy makers’ decision to replace existing anti-malarials, such as sulphadoxine-
pyrimethamine (SP) with “new” treatment regimens, such as ALu or other formulations of ACT. This study was
conducted to examine community level understandings and interpretations of ALu’s efficacy and side-effects. The
paper specifically examines the perceived efficacy of ALu as articulated by the mothers of young children
diagnosed with malaria and prescribed ALu.
Methods: Participant observation, six focus group discussions in two large villages, followed by interviews with a
random sample of 110 mothers of children less than five years of age, who were diagnosed with malaria and
prescribed ALu. Additionally, observations were conducted in two village dispensaries involving interactions
between mothers/caretakers and health care providers.
Results: While more than two-thirds of the mothers had an overall negative disposition toward SP, 97.5% of them
spoke favourably about ALu, emphasizing it’s ability to help their children to rapidly recover from malaria, without
undesirable side-effects. 62.5% of the mothers reported that they were spending less money dealing with malaria
than previously when their child was treated with SP. 88% of the mothers had waited for 48 hours or more after
the onset of fever before taking their child to the dispensary. Mothers’ knowledge and reporting of ALu’s dosage
was, in many cases, inconsistent with the recommended dosage schedule for children.
Conclusion: Deployment of ALu has significantly changed community level perceptions of anti-malarial treatment.
However, mothers continue to delay seeking care before accessing ALu, limiting the impact of highly subsidized
rollout of the drug. Implementation of ACT-based treatment guidelines must be complemented with educational
campaigns to insure that mothers seek prompt help for their children within 24 hours of the onset of fever.
Improved communication between health care providers and mothers of sick children can facilitate better
adherence to ALu’s recommended dosage. Community level interpretations of anti-malarials are multifaceted;
integrating knowledge of local beliefs and practices surrounding consumption of anti-malarials into programmatic
goals can help to significantly improve malaria control interventions.
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Background
In December 2006, Tanzania implemented new malaria
treatment guidelines requiring the large scale deploy-
ment of Coartem® (Novartis), a fixed-dose artemether/
lumefantrine-based combination therapy (ACT) popu-
larly known as ALu or dawa mseto in public health
facilities, to treat uncomplicated malaria [1]. These new
guidelines were implemented five years after the govern-
ment decided to replace chloroquine (CQ) with sulpha-
doxine-pyrimethamine (SP) as the first-line treatment
for uncomplicated malaria. Studies detailing how people
in malaria endemic areas interpret policy makers’ deci-
sions to replace existing anti-malarials, such as SP, with
“new” treatments, such as ALu or another artemisinin-
based combination therapy (ACT), are lacking. Examin-
ing how adults and children use a newly introduced
drug can inform the design of interventions aimed at
improving drug use and therapeutic outcomes in com-
munity settings [2-4].
Documenting community level understandings and
interpretations of ALu’s efficacy and side effects is
important for several reasons. First, the deployment of
ACT on a large scale marks a major shift in global dis-
courses on malaria control, mainly because ACT is a
very expensive therapy that is unsustainable in poor
countries like Tanzania without substantial donor fund-
ing [5,6]. Second, ACT is often described as “the key
weapon” in the fight against malarial parasites because
there are few affordable alternatives to ACT [7,8]. Third,
researchers fear that malaria parasites could develop
resistance to component drugs in ACT, due to the inap-
propriate use of artemisinin monotherapies [9,10].
Finally, medical anthropologists in particular have con-
sistently pointed out that the perceived efficacy of a
drug is embedded in culturally specific expectations.
Thus, the perceived efficacy and side effects of anti-
malarials must be examined in specific cultural or com-
munity contexts [11-13]. Although some researchers
have examined community level perspectives on SP
among populations severely affected by malaria [14,15],
there is very little information on the community level
perceptions of ALu after the Tanzanian government
introduced it on a large scale. Understanding how cul-
tural perceptions influence decisions regarding the use
and consumption of anti-malarials, both “old” and
“new,” can provide valuable insights into how the deliv-
ery of newer treatment regimens can be better managed.
Determining the efficacy and side effects of anti-
malarials is a complex task, both in biomedical and
behavioural terms. This is especially true when the
patients are young children who have been treated with
anti-malarials, and mothers do the reporting on their
children’s behalf [16]. Many researchers have pointed
out that there are significant discrepancies between
reported consumption of anti-malarials, efficacy and
detectable levels of the specific anti-malarial found in
blood samples [3,14]. As such, the goal of this paper is
to examine the perceived efficacy of ALu as articulated
by the mothers of young children diagnosed with
malaria and prescribed ALu. Though limited in its
scope, this approach, which may be characterized as
“interpretive,” is important because the success or failure
of an anti-malarial treatment policy will ultimately
depend on the perceptions and understanding about the
drug’s efficacy at the community level [13]. Given that
people’s prior experiences and perceptions significantly
influence the extent to which they “adhere” to the new
ACT drug regimen, community level studies of percep-
tions of malaria and anti-malarials can provide useful
perspectives on how people interpret the efficacy of
“new” anti-malarials in light of their experience with
“old” anti-malarials. In Tanzania, for example, research-
ers have documented that, while many people have a
negative disposition toward SP, they are nostalgic when
talking about CQ, emphasizing that they would be very
pleased if they had access to CQ because it was an inex-
pensive drug, which brought immediate relief to the
patient due to its antipyretic effect [14,16].
Methods
Study area and population
This study was conducted in the Chamazi administrative
ward of Temeke District, Dar es Salaam (population: 3.5
million), Tanzania’s commercial capital, which com-
prises of three independently governed municipalities -
Temeke, Ilala and Kinondoni. Temeke district, with a
population of 886,529 in 2007, and an area of 656 sq.
km. is the largest of the three districts that comprise
Dar es Salaam. Chamazi ward, which is located some 25
km south of Dar es Salaam’s central business district,
has two large villages – Chamazi proper (pop. 10,000)
and Mbande (pop. 8,000). A number of small villages
and hamlets surround these two large villages. 85% of
the local residents are Muslims. While the majority of
the local residents identify themselves as Zaramo, there
are substantial numbers of people in these villages who
identify themselves as Makonde, Matumbi, Mpogoro,
Ndengereko, Ngindo, Nyamwezi, Msukuma and Myao,
among others. Cash income is scarce for many of the
local residents whose economic base is subsistence-
oriented farming. The completion of the all-weather
road in 1996, which connects the trading town of Mba-
gala with Mbande village, marked the beginning of a
new wave of migrants into this region, mostly from
north-western and south-eastern Tanzania. The road
facilitated the rapid transportation of people and goods
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between the villages and the city. The local health arena
is pluralistic as villagers have access to municipal dis-
pensaries - one of which is located in Chamazi village
and the other in Mbande village. Both dispensaries are
generally well staffed and well stocked. Additionally, in
Chamazi ward, there are more than ten registered “tra-
ditional healers” (waganga), two licensed private practi-
tioner’s clinics, and 14 drug stores (duka la dawa
baridi), which are managed by people without adequate
formal training.
Data collection
Data were gathered during four months of fieldwork
(May to August of 2007) in the Chamazi ward. Addi-
tional follow-up research led by the second author was
undertaken during the months of July and August 2009.
Data were gathered using a combination of participant
observation in the villages and at the health facilities,
exploratory focus group discussions (FGDs) and semi-
structured interviews with mothers of children below
five years of age, who were diagnosed with malaria and
treated with ALu less than two weeks prior to the inter-
view. All interviews were conducted in Kiswahili with
the help of an experienced female research assistant.
The first author interacted with all the interviewees and
was present during all the interviews. The second author
conducted follow-up interviews, organized FGDs, made
observations at the dispensaries, and translated the
interviews from Kiswahili to English.
Focus group discussions
FGDs were conducted in Mbande and Chamazi with six
groups of six to eight mothers (total 42 participants).
Two field assistants who were local residents initially
approached mothers of young children who were diag-
nosed with malaria and treated with ALu at the local
municipal dispensary, and invited them to participate in
the FGDs. Those who were recruited at the dispensaries
and were willing to participate in the FGDs were given
further details about the study, the venue for the FGDs,
and their role in generating important information for
the study through discussions in small groups with the
help of a moderator. Some of the key questions and
topics addressed in the focus groups were: symptoms
that prompt mothers to take their sick children to the
dispensary; reasons why mothers delay seeking prompt
treatment for their children when they have high fever;
participants’ opinion regarding the changes they have
noticed in the quality of treatment for malaria since SP
was replaced with ALu as the first-line drug at public
health facilities; their perceptions regarding the side-
effects associated with SP and ALu; their perceptions
regarding the cost of dealing with childhood malaria;
measures taken by members of the community to
protect their children from contracting malaria; whether
in their view, the malaria situation in their village has
improved since the introduction of ALu, and what
according to them needs to be done to minimize malar-
ia’s impact on their community.
Semi-structured interviews
After reviewing the data from the FGDs and refining the
semi-structured interview schedule, detailed interviews
were conducted with 110 mothers whose children were
treated with ALu for malaria during the past two weeks,
in Mbande, Chamazi, and three adjoining villages –
Wembebamia, Kiponza and Kisewe. Mothers were ran-
domly selected from a list that was prepared following
initial contacts with them at the dispensaries. Only
those who were willing to participate in the study were
interviewed. Mothers were interviewed regarding the
child who was under five years of age, diagnosed with
malaria and prescribed ALu at the local municipal dis-
pensary less than two weeks before the interview. Two
children in the study sample had been treated with ALu
followed by another anti-malarial, such as quinine (QN)
or antibiotics.
Mothers were asked to describe the symptoms that
had prompted them to take their child to the municipal
dispensary; the time between the onset of symptoms
and their decision to take the child to the dispensary;
the advice they had received from the doctor or the
nurse at the dispensary; the period they had waited
before concluding that their child had recovered from
his or her illness; whether their child had experienced
any undesirable bodily side effects (madhara) after
being treated with ALu, and if so, to describe the side
effects. Mothers were also asked to describe their
experience of treating their children with ALu, and how
these compared with their experiences of SP. Finally, as
a closing question, they were asked to express their
thoughts on why they believed malaria persisted in their
respective villages.
Additionally, interactions between mothers with sick
children and the health workers at the municipal dis-
pensaries, surrounding the dispensing of ALu, were
observed, focusing mainly on the advice given by the
nurse to the mothers at the dispensing counter.
Data analysis
All mothers who agreed to participate in the study gave
their oral consent for the interview. Interviews lasting
about 30 minutes were recorded on a digital audio-
recorder, transcribed verbatim in Kiswahili and key pas-
sages were later translated into English. Quantitative
data from the recorded interviews were entered into a
spreadsheet and processed using Microsoft Excel®. The
authors reviewed all the interview transcripts and
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extracted segments and passages that called for a closer
analysis, which were then manually encoded and ana-
lysed. “Text” or qualitative data from FGDs and inter-
views were first entered in MicrosoftWord® and
processed using ATLAS.ti 6.0 for key words and quotes,
and themes. Notes from the field diary were incorpo-
rated into the analysis.
Ethical Review
Permission to conduct this study was given by the Tan-
zania Commission for Science and Technology (COST-
ECH Permit No. 2006-366-CC-2005-36). The
Behavioural Research Ethical Board, University of British
Columbia, and the Medical Research Coordinating
Committee of the National Malaria Research Institute,
Dar es Salaam gave ethics clearance for this study. Addi-
tional research and ethics clearance was obtained from
the University of Dodoma.
Results
Demographic information on the 110 mothers inter-
viewed for this study is presented in Table 1. Of the
children whose mothers were interviewed (index child),
51% were male and 49% were female. Their average age
was 38 months (range three months to 60 months).
Symptom recognition, waiting period and therapy-
seeking
While early detection and access to prompt, affordable
and effective treatment is regarded as the cornerstone of
a successful malaria control strategy[17], in the present
study, only 12% of the mothers had taken their child to
the dispensary within 24 hours after noticing that he/
she had a fever. 35% of the mothers had waited for two
days (48 hours); 34% had waited for three days (72
hours) and the remaining 19% had waited between four
and six days (92+ hours) before taking their child to the
dispensary. While the majority (81%) of the mothers
had treated their child’s fever with a store-bought anti-
pyretic such as Panadol® (paracetamol) a small number
(2.5%) had used Panadol® in combination with SP.
Another 2.5% had given their child SP albeit to no avail.
14% of the mothers had not given their child any medi-
cation before taking him/her to the dispensary.
Nearly 90% of the mothers mentioned high fever or
persistent fever as the most important symptom influen-
cing their decision to take their child to the dispensary.
They denoted key symptoms by using terms and phrases
such as homa kali (high fever) or mwili ulichemka (the
body temperature was very high), (22.5%), homa
haishuki (the fever wouldn’t come down), (34%), homa
ilikuwa inatisha (the fever was frightening) (6%), hali
iliharibika zaidi (the condition worsened) (20%), hali ya
mtoto haikuboreka (the child’s condition did not
improve), (7.5%), and alichoka na kutapika (he/she was
exhausted and vomited) (2.5%). The remaining 7.5% had
taken their child to the dispensary “without thinking too
much about it,” mainly to get the doctor’s advice. Thus,
the key symptom prompting mothers to consider taking
their sick child to the dispensary is high fever that does
not subside following treatment with an antipyretic.
However, observational data gathered at the two munici-
pal dispensaries revealed that in addition to persistent
high fever, mothers also mentioned alitapika (vomiting),
aliharisha (diarrhoea) and ananyongea (bodily weak-
ness) as other symptoms that had prompted them to
take their sick child to the dispensary.
Treatment recall and perceived efficacy
While 80% of the mothers reported that their child was
prescribed ALu along with an antipyretic, often recognized
as Panadol® or Panadol syrup (Panadol ya maji), 15% of
them reported that their child was prescribed only ALu.
Table 1 Background information on mothers interviewed
for the study (n = 110)
Residence n %
Chamazi Kwamkongo 30 27.27
Kiponza 13 11.83
Kisewe 29 26.36
Mbande Kijiji 31 28.18
Wembebamia 07 6.36
Age
17-21 15 13.63
22-26 38 34.54
27-31 26 23.63
32-36 10 9.10
40-50 21 19.10
Education
Nil 16 14.55
Primary school years 1-6 18 16.36
Primary school year 7 70 63.64
Primary school year 8 2 1.81
Secondary school Form 2 4 3.64
Marital Status
Married 57 51.82
Unmarried 34 30.91
Widow 2 1.81
Divorced 17 15.46
Religion
Muslim 91 82.73
Christian 19 17.27
Number of Children
1 36 32.73
2 32 29.09
3 20 18.18
4 14 12.73
5-7 8 7.27
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The remaining 5% of the mothers said that their child was
prescribed ALu along with Panadol® and either a cough
syrup or a packet of oral rehydration solution (ORS). Sig-
nificantly, 92.5% of the mothers had taken their child to
the dispensary only once. The remaining 7.5% of the
mothers had gone to the dispensary at least twice because
their child’s condition had not improved even after com-
pleting the dosage. Four children in the study sample had
received further treatment at the district hospital, and two
others were taken to the Muhimbili National Hospital
(MNH) located 30 km away.
Focusing on perceptions of ALu’s curative efficacy,
mothers were asked whether they believed ALu was an
effective drug in the treatment of malaria. Responses to
the above question, coded retrospectively as positive or
negative revealed that 97.5% of the mothers had an
overall positive disposition toward ALu. They confi-
dently stated dawa inafaa, amepona kabisa, anaendelea
vizuri tu (the drug is effective, the child has completely
recovered, and is doing well) (55%); anaendelea vizuri,
anacheza na anachangamka vizuri (the child is doing
fine, and is very active) (42.5%) to indicate that their
child had completely recovered following treatment with
ALu. Two mothers were uncertain if their child had
completely recovered. Significantly, the data in Table 2
reveal that although all the index children in the study
were prescribed ALu at the local dispensary, in many
cases mothers’ knowledge and reporting of the dosage
schedule was inconsistent with the recommended
dosage for their children.
Perceived efficacy and side effects of ALu compared
with SP
94% of the mothers reported that they had not noticed
any madhara or “undesirable” side effect in their child
who was most recently treated with ALu. They emphati-
cally stated that they had not seen any side effects and
the drug had helped the child to recover completely.
The remaining five mothers mentioned various side
effects including the worsening of the child’s fever. By
contrast, when asked to compare their experiences with
SP, a majority of the mothers recalled a range of unde-
sirable madhara they believed were caused by SP such
as inachokesha, mtoto ana legea sana (causes extreme
exhaustion, the child become very weak), homa
haishuki, haipungui, iko pale pale wiki nzima (the fever
does not go away for a week), inaleta vipele mdomoni,
mapele mwilini (it results in mouth ulcers and rashes
on the body), kuwashwa washwa (there’s itching all over
the body) and anakuwa na marengerenge (he/she devel-
opes impetigo), mtoto hatulii (the child becomes rest-
less). A 40-year-old mother of three children explained:
My son became very weak after he was treated with
SP. I thought to myself “Have we treated the illness
or have we worsened it?!” It took about two weeks for
him to return to his normal self. But last week when
he had malaria, he was treated with ALu; he woke
up in the morning and started playing as usual and
his condition returned to normal.
Perceptions of ALu’s efficacy were closely tied to the
perceived cost of dealing with a child’s malaria episode.
More than 90% of the mothers emphatically stated that
ALu was far superior to SP because of its long-lasting
effect, and also because the process of treatment-seeking
was less expensive. A 27-year-old mother of a three-year
old child contextualized her experience with ALu and
SP as follows:
It’s a lot better now because ALu really helps. Earlier
you had to pay to get SP, which in any case did not
help; the fever wouldn’t go away so you had to take
your child to the dispensary three or four times. By
then you’ll have exhausted all your money. But now
it’s different; the medicine is good. At the dispensary
they also do a blood test. If your child is treated with
ALu, he’ll get better right away. The medicine of
today is genuine (dawa za uhakika). If you use it
once, you get better right away, so there’s no need to
go to the dispensary again and again.
Perceptions of the drug’s efficacy were also reflected in
statements about the expenses incurred in the treatment
of childhood malaria. 62.5% of the mothers reported
spending less money treating malaria than when SP was
the first-line drug. Owing to the fact that ALu was pre-
scribed to them free of cost at the local dispensary and
treatment seeking did not involve multiple trips to the
Table 2 Mothers’ recall of ALu’s dosage (n = 110)
Dosage recall n %
Twice a day for three days, six tablets in total 63 57.30
Three times a day for three days 11 10.00
Two times a day for five days 4 3.64
Two times a day for six days 3 2.72
Three times a day for six days 4 3.64
Two times a day for seven days 3 2.72
One tablet for seven days 5 4.55
Half a tablet, three times a day for seven days 3 2.72
Half a tablet, twice a day for seven days 2 1.81
Half a tablet, twice a day for two days 1 .90
Quarter tablet, three times a day for three days 2 1.81
One table a day for five days 2 1.81
Forgot the dose, cannot recall 7 6.36
Note: For children in the 4 months to 5 years age group, weighing between 5
and 14 kilos, the standard recommended dose of artemether-lumefantrine is
one tablet, twice a day after a gap of 8 hours, for three days in total
(Guidelines for the treatment of malaria, WHO 2006).
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health facilities, they could “afford” to deal with a malaria
episode. However, 30% said that dealing with malaria had
become more expensive than before, although many of
them added that while SP was a relatively inexpensive
drug, they could not trust it because it took a lot longer
for the drug to work and they had to make multiple trips
to health facilities. The remaining 7.5% of the mothers
said that they did not find any significant difference in the
expenses incurred during the SP era and now.
Advice
95% of the mothers had received at least some advice
from the dispensary staff along with a prescription for
ALu. 77.5% reported that they were told to continue
giving Panadol® to their child and to return to the dis-
pensary if the fever did not go away after three days.
Another 17.5% were specifically told to keep their house
and surroundings clean by clearing the grass, and to use
an ITN to minimize mosquito bites. The remaining 5%
of the mothers stated that they had not received any
advice from the dispensary staff. Observational data
revealed that the dispensary staff, usually one of the
nurses, spent an average of two minutes advising the
mothers on how to use ALu and reminding them that
they need to give their child plenty of water to drink
during the treatment period.
Perceptions of malaria’s persistence
While all mothers who participated in the FGDs and nearly
90% of those who were interviewed said that they were
satisfied with ALu’s efficacy, they frequently exclaimed
malaria iko nyingi! meaning that there was still a lot of
malaria in their respective villages. Elaborating on their
response, more than 75% of the mothers attributed the
persistence of malaria in their respective villages to poverty
and poor environmental conditions (mazingira machafu).
A 40-year-old mother of four children explained:
We are poor so we don’t have enough nets for every-
one in the house. When our relatives come to visit us,
we’ll say, Ah! Alright, let the guests sleep there under
the net, and I’ll sleep on this side with my children
without a net. Naturally the mosquitoes bite us and
we get malaria. What can we do? We are poor.
There are many large families in this village who
have only one net, and many people sleep in places
where there are no nets at all.
Mothers gave multiple responses to describe their
efforts to minimize the impact of malaria on their lives –
use of ITNs to prevent mosquito bites (76.5%) and cover-
ing the bed with an ITN early during the evening; keep-
ing surroundings clean (76%) and making sure that
children wear a sweater in the evenings before going to
bed to prevent mosquitoes from biting them (27.5%)
Discussion
The Tanzanian government’s decision to deploy ALu as
the first-line anti-malarial on a large scale, mainly
through public health facilities, is laudable from a public
health point of view. This decision, however, also invites
more attention to how communities that are affected by
malaria interpret the efficacy and side effects of newer
and older anti-malarials. Monitoring how the introduc-
tion of new anti-malarials affects people’s treatment
expectations, the cultural meanings they attribute to old
and new drugs, their reckoning of the cost factor in
their search for therapy, and their responses to uncer-
tainty in the context of poverty is critical for the suc-
cessful deployment of new anti-malarial regimens.
The data from this study suggest that even though
mothers are aware that they have access to a highly
effective anti-malarial free of cost, the majority (88%) of
them do not rush their child to a health facility for diag-
nosis and treatment within 24 hours of the onset of
fever. Instead, they first treat their febrile child with a
store-bought antipyretic to see if the fever subsides.
They continuously monitor and evaluate their child’s
fever for up to three days, and in some cases for up to
six days, before deciding to take him/her to a health
facility. The data also suggest that self-treatment of feb-
rile children with a store-bought anti-malarial in the
Dar es Salaam region is uncommon. This observation is
consistent with findings of recent studies in the Tanza-
nian context, which have reported that unlike during
the chloroquine era when self-medication was the norm,
there is a noticeable reluctance among the people of
Tanzania to use a store-bought anti-malarial to treat
childhood malaria as a first resort [14,18-20].
The data also suggest that mothers who participated
in FGDs and those who were interviewed for this study
were satisfied with ALu’s therapeutic efficacy as well as
what it costs them to access the drug; they were equally
pleased with the fact that the personnel at the local dis-
pensary perform a blood test (vipimo) on their children
to confirm that they have malaria before prescribing
ALu. While this often leads to longer waiting periods,
not one mother in the study complained about the
extended waiting periods at the dispensary. Thus,
improved perception of ALu is related to improved per-
ception of the quality of care exemplified by blood tests
for malaria. These data are striking when compared to
mothers’ responses regarding sick children to a similar
question pertaining to treatment with SP in a previous
study in the same research setting [16]. In the previous
study, 32% of the mothers were not satisfied with the
treatment that their child had received at the first place
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of medical consultation and nearly 50% of the mothers
attributed their child’s recovery from the illness to a
medicine/treatment other than SP given at the local
municipal dispensary.
For the majority of the mothers interviewed for this
study, the blood test marks a significant departure from
the SP era when children were routinely/clinically diag-
nosed with malaria and presumptively prescribed SP,
even as the majority of the mothers deemed it a useless
and/or a dangerous drug. In addition to efficacy, cost
entered the evaluation of anti-malarials. During the SP
era, dealing with childhood malaria was usually an
expensive undertaking. In the previous study up to 59%
of the mothers had consulted more than one health
facility in search of an alternative therapy for their sick
child. In the process they had incurred additional
expenses and lost precious time [16]. The financial bur-
den increased exponentially from CQ to SP for mothers
of febrile children, especially those who lacked a strong
support network to help them out during a health crisis.
Faced with repeated treatment failure, mothers sought
treatment from multiple sources, incurring additional
costs and other burdens. By contrast, the introduction
of ALu has significantly changed the situation, as most
of the mothers who participated in this study believed
that they were spending significantly less money on
dealing with a malaria episode than before. Although
mothers identified ALu as cost-effective, as noted ear-
lier, the majority of them had delayed in bringing their
sick children to a health facility because they thought
they were dealing with an ordinary fever (homa ya
kawaida) or teething fever (mtoto anaota meno). Most
of the mothers had decided to “wait and see” (unasubiri
ukimtazamia) if the fever would go away following
treatment with a store-bought antipyretic. These obser-
vations are significant in the context of recent discus-
sions and debates surrounding the accuracy of malaria
diagnosis, misdiagnosis, over-diagnosis, and the question
whether to treat all fever cases presumptively with an
anti-malarial or to rely on laboratory-confirmed diagno-
sis and treatment [21,22]. On the one hand, it may be
argued that mothers who resort to a store-bought anti-
pyretic and engage in a “wait and see” approach before
deciding whether to rush the child to the dispensary or
not, may in fact be minimizing the chances of their
child being wrongly diagnosed and unnecessarily pre-
scribed an anti-malarial. On the other hand, it may be
argued that the ease with which mothers are able to
obtain ALu, a highly effective anti-malarial at the dis-
pensary, free of cost, may in fact be a key deterrent in
their decision to rush their febrile child to the dispen-
sary within 24 hours of the onset of fever. Experienced
mothers in Dar es Salaam know fully well that if their
child’s condition were to worsen, they would most
certainly get ALu at the dispensary that would enable
their child to recover rapidly.
While plans are being implemented to provide the
public with better access to ACT, there is an urgent
need to implement socio-cultural and behavioural inter-
ventions that would persuade mothers to bring their
sick children to a health facility for diagnosis and treat-
ment within 24 hours of the onset of symptoms, and
not wait for three or more days to see if the fever would
subside with an antipyretic. This would minimize child-
hood mortality resulting from other severe febrile ill-
nesses, such as pneumonia or meningitis, which cannot
be easily managed at home [23]. Concurrently, these
behavioural interventions will have to be accompanied
by “technical” interventions to ensure more accurate
diagnosis and appropriate treatment of febrile children.
Further, health care providers need to be better trained
to communicate more effectively with mothers whose
children have been diagnosed with malaria. Many stu-
dies have reported that health care providers, especially
in public health facilities in Tanzania, do not communi-
cate well with their patients, as they frequently fail to
inform them of the nature of the illness and details of
the prescription [24,25].
This is especially true in situations where, due to
shortage of drugs, health care providers may give Coar-
tem® blister package meant for adults to mothers, ask-
ing them to break up the tablets into two or four parts,
and give them to their febrile children. In the present
case, the discrepancy between the recommended dosage
and schedule for ALu and the mothers’ reporting of the
dosage and schedule they adhered to (see Table 2), may
be due to a combination of poor adherence, reporting
problems, problems in recall, and insufficient communi-
cation between the health staff at the dispensary and the
mothers. However, it is important to address the issue
of discrepancy between recommended dosage and sche-
dule and the patient’s adherence to the correct drug
regimen because partially effective treatment may result
in recrudescence of the infection, and in the long run,
contribute to the development of anti-malarial drug
resistance [3,26,27].
This study has some limitations that should be consid-
ered. First, the study was conducted in a region and
among a population that is relatively well served by the
health care system, and where people have access to
ACT. Caution must be exercised in extrapolating the
findings of the study to other regions of Tanzania where
there are remarkable differences in population config-
urations, health infrastructure, and people’s access to
ACT. Second, the sample size is relatively small to make
major statistical inferences. Third, a bulk of the data
analysed for this study is derived from narrative inter-
views with mothers. It was beyond the scope of the
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study to verify their reports about the drug’s efficacy
through other measures, including ascertaining drug
levels in blood samples. The findings of this study are,
therefore, context-based and limited in their generaliz-
ability. However, the findings of this study provide valu-
able insights into how community level interpretations
of newly introduced anti-malarials can inform further
research and policy decisions aimed at improving the
coverage and delivery of ACT among economically vul-
nerable populations.
Conclusion
The deployment of ALu in public health facilities for
treatment of uncomplicated malaria has significantly
altered people’s perceptions of anti-malarial treatment.
In the present study, the majority of the mothers not
only regarded ALu as an effective anti-malarial, they
also found that it significantly reduced their expenditure
on dealing with a malarial episode because it did not
require them to go through multiple treatment stages as
was common during the SP era. However, the majority
of the mothers delayed before accessing ALu, limiting
the impact of the subsidized roll out of these drugs on
health outcomes. Current efforts to make highly subsi-
dized ACT more readily available through private retail
pharmacies may result in patients being promptly
treated with a highly effective anti-malarial. However,
this complex intervention may also result in people’s
overdependence on the commercial sector for treatment
of childhood fevers, and lead to additional financial bur-
den on poor households [25,28]. Further, the results
highlight the importance of educational campaigns to
refine prompt treatment-seeking messages targeted at
families by taking into account community beliefs and
practices. It is important to continuously monitor peo-
ple’s discourse on treatment decisions, alternative
courses of possible action, and to document how they
interpret the efficacy and side effects of anti-malarials
that are deployed as first-line drugs, and their treatment
expectations and perceptions of medicine compatibility.
At a time when approaches to dealing with malaria are
becoming increasingly treatment-oriented, community-
based behavioural research can remind us that the
efficacy of anti-malarials is multifaceted. It is one thing
to demonstrate the in vivo clinical or pharmacological
efficacy of various anti-malarials in controlled environ-
ments, and quite another to ensure the effectiveness of
the drugs in “real-life” situations [29]. In other words,
anti-malarials, which reveal excellent efficacy under con-
trolled clinical trial conditions, may not demonstrate
equally excellent “effectiveness” when they are deployed
widely under real-life conditions [3]. Successful delivery
of effective malaria treatment requires that health plan-
ners do not downplay the broader socio-cultural,
economic, technical, and political environments in
which treatment regimens are implemented [30]. Thus,
a lot more is at stake in malaria control than the rolling
out of highly subsidized, highly efficacious ACT. Inte-
grating knowledge of local beliefs and practices sur-
rounding consumption of anti-malarials into
programmatic goals can be immensely valuable in
improving the rigor and effectiveness of malaria control
interventions [31].
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